• Walid Shalata, Rachel Steckbeck, Amjad Abu Salman, Abu SalehOmarODepartment of Dermatology and Venereology, Emek Medical Centre, Afula 18341, Israel., Ashraf Abu Jama, Zoé Gabrielle Attal, Sondos Shalata, Hilmi Alnsasra, and Alexander Yakobson.
• The Legacy Heritage Oncology Center and Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva 84105, Israel.
• Medicina (Kaunas). 2024 Jan 28; 60 (2).

AbstractPatient prognoses have been significantly enhanced by immune checkpoint inhibitors (ICIs), altering the standard of care in cancer treatment. These novel antibodies have become a mainstay of care for metastatic non-small-cell lung cancer (mNSCLC) patients. Several types of adverse events related to ICIs have been identified and documented as a result of the launch of these innovative medicines. We present here a 74-year-old female patient with a stage IV lung adenocarcinoma, treated with nivolumab plus ipilimumab, who developed perimyocarditis two weeks after receiving the third cycle of immune checkpoint inhibitor therapy. The patient was diagnosed using troponin levels, computed tomography (CT) angiography, and echocardiography. After hospitalization, her cardiac condition was successfully resolved with corticosteroids, colchicine, and symptomatic treatment. To the best of our knowledge, this is one of the rarest cases to be reported of perimyocarditis as a toxicity of immunotherapy in a patient treated for adenocarcinoma of the lung.

23 keywords...

hide…